알츠하이머병에 대한 근거중심 처방 = Evidence-Based Treatment of Alzheimer’s Disease

다국어 초록 (Multilingual Abstract)

The pharmacological treatment of Alzheimer’s disease is based on symptomatic therapy of

cognitive decline and behavioral problems. Numerous therapies have been investigated for

the treatment and prevention of Alzheimer’s disease. We reviewed the current evidence-based

medical research and guidelines of treatment for Alzheimer’s disease. The use of cholinesterase

inhibitors (ChEI) and N-methyl-D-aspartate (NMDA) inhibitors can bring about significant but

modest therapeutic improvement. There is insufficient evidence to recommend vitamine E,

estrogen, ginko biloba, or nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention or

treatment of Alzheimer’s disease. This article reviews the available data on current pharmacological

treatments through evidence-based medicine.

참고문헌 (Reference)

1 Fillit HM, "Recommendations for best practices in the treatment of Alzheimer’s disease in managed care" 4S : 9-24, 2006

2 American Psychiatric Association, "Practice guideline for the treatment of patients with Alzheimer's disease and other dementias 2nd Edition" 1-86, 2007

3 Kim KW, "Cognitive enhancers. in: Korean Association for Geriatric Psychiatry. Geriatric Psychiatry, 2nd ed" Jungangmunwha Co 2004

4 "California Workgroup on Guidelines for Alzheimer’s Disease Management. Guideline for Alzheimer’s Disease Management" 2008

5 Burns A, "BAP Dementia Consensus group. British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology" 20 : 732-755, 2006